CClinicalTrials.gg
CompletedNCT07330791Updated Jan 9, 2026

Right Phrenic Nerve Localization on CT for Ablation

An observational study in We Evaluated CT-guided Localization of the Right Phrenic Nerve to Enhance Safety in Transcatheter Ablation, sponsored by Centro Medico Teknon. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Centro Medico Teknon · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Study summary

The anatomical location of the right phrenic nerve (RPN) in close proximity to the right pulmonary veins has become a critical consideration for electrophysiologists performing pulmonary vein isolation, the cornerstone treatment for atrial fibrillation. Although radiofrequency ablation in this region is rarely associated with complications-unlike cryoballoon ablation-the proximity of the RPN to the ablation site is considered the most widely accepted mechanism of nerve injury. Therefore, accurately defining its anatomical course is essential to prevent complications.

This concern extends to any ablation procedure performed near the RPN, including those targeting the lateral-posterior region of the right atrium, particularly during atrial tachycardia ablation or cardioneuroablation. Several methods have been used to precisely localize the RPN. The most commonly employed technique is phrenic nerve stimulation; however, there is growing interest in the use of computed tomography (CT) to identify structures running parallel to the nerve-such as the pericardiophrenic artery and vein-enhanced with contrast. Three-dimensional reconstruction through image segmentation has proven useful in defining the anatomy of cardiac chambers and adjacent extracardiac structures.

This study aims to compare two approaches for visualizing the course of the right phrenic nerve: one based on computed tomography imaging and the other on the nerve's response to stimulation during the procedure. This comparison will allow us to assess the concordance between imaging findings and intra-procedural observations, ultimately contributing to improved procedural safety.

02

Conditions studied

  • We Evaluated CT-guided Localization of the Right Phrenic Nerve to Enhance Safety in Transcatheter Ablation

Keywords

  • Right Phrenic Nerve
  • Phrenic Nerve Localization
  • Computed Tomography
  • CT-Guided Imaging
  • Radiofrequency Ablation
  • Catheter Ablation
  • Transcatheter Ablation Safety
  • Cardiac Ablation Complications
  • Ablation Procedures
  • Phrenic Nerve Injury
03

In context

Lead sponsor

Centro Medico Teknon is the lead sponsor of 20 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients underwent an electrocardiography-gated cardiovascular CT using a 64-slice multidetector row CT scanner (Revolution CT, GE Healthcare Global Diagnostic Imaging) prior to the ablation procedure. The position line was set at 0.5 cm below the tracheal bifurcation to the cardiac diaphragmatic surface. The acquisition was performed within a single breath- hold. The gantry rotation time was 0.35 s, and the tube current was 350-750 mA at 120 kV. Iodinated contrast material (60 mL; Omnipaque 300 mg/mL), was injected at a rate of 4-5 mL/s, followed by 20 mL of saline solution. A second acquisition immediately after is performed to study the venous phase. Original images at 75% or 45% R-R intervals were transferred to post-processing Workstation, with a section thickness of 0.625 mm. If motion artifacts appeared, the electrocardiographic editing technique was used and the reconstructed window was moved forward or backward for 5% R-R interval until the motion artifacts disappeared.

Inclusion criteria

  • Ability to provide informed consent
  • Patients who have undergone or will undergo transcatheter AF ablation or CNA
  • Availability of 64-slice contrast-enhanced MDCT with RPN segmentation using ADAS® software prior to ablation
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Inability to provide informed consent
  • Inability to perform contrast-enhanced CT before transcatheter AF ablation or CNA
  • Age \< 18 years
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • This study will enroll patients undergoing two distinct types of ablative procedures g

    A total of 80 consecutive patients will be included: * 60 patients will be enrolled using a single electric stimulation output set at 20 mA, 2 ms amplitude width and 1000 ms cycle length * 20 patients will be enrolled using a double electric stimulation output set respectively at 10 mA and 20 mA (2 ms amplitude width and 1000 ms cycle length)

06

What researchers measure

Primary outcomes

  1. analyse the anatomy of the RPN

    The primary endpoint of this study is to analyse the anatomy of the RPN using three-dimensional (3D) imaging and iso-distance mapping with ADAS® software, and to validate its accuracy through traditional pace mapping.

    Time frame: From January 2021 to April 2025

  2. Accuracy of Imaging-Guided Anatomical Localization of the Phrenic Nerve with ADAS® software Compared With Conventional Pacemapping

    The positions as observed by the 2 different methods are compared and the correlation was expressed as a percentage. Global image correlation is computed as the mean correlation between methods.

    Time frame: from the procedure to 12 months later

07

Study locations

1 site
  • Antonio Berruezo
    Barcelona, Barcelona 08022, Spain
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07330791
Lead sponsor
Centro Medico Teknon
Responsible party
Antonio Berruezo, MD, PhD (Chief of Electrophysiology Unit, Centro Medico Teknon) — Principal investigator
First posted
Jan 9, 2026
Start date
Apr 1, 2025
Primary completion
Sep 20, 2025
Completion
Sep 29, 2025
Last update
Jan 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion